{
    "clinical_study": {
        "@rank": "31933", 
        "arm_group": [
            {
                "arm_group_label": "ARM 1: AdMSC: stem cells", 
                "arm_group_type": "Experimental", 
                "description": "AdMSC: Autologous adipose tissue-derived mesenchymal stem cell"
            }, 
            {
                "arm_group_label": "ARM 2 Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. For those subjects in the placebo arm, the stem cells will be frozen for later use after one year when the patients cross over into the treatment arm."
            }
        ], 
        "brief_summary": {
            "textblock": "Men who present with erectile dysfunction as defined as an IIEF (International Index of\n      Erectile Function) score less than 21 will be evaluated for risk factors for cardiovascular\n      disease (CVD).  This is a single-blind study. Subjects will be randomized in a 2:1 fashion\n      for treatment (ARM 1) versus placebo (ARM 2).  Adipose tissue (fat) will be harvested from\n      all patients and stem cells will be cultured.  For those patients in the placebo arm the\n      stem cells will be frozen for later use after one year when the patients cross over into the\n      treatment arm."
        }, 
        "brief_title": "Stem Cells for the Improvement of Erectile and Cardiac Function in Aging Men", 
        "condition": [
            "Erectile Dysfunction", 
            "Cardiac Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Heart Diseases", 
                "Erectile Dysfunction"
            ]
        }, 
        "detailed_description": {
            "textblock": "Baseline assessment of patients will include completion of 6 questionnaires, EKG\n      (electrocardiogram), vision testing using a standard eye chart, markers of endothelial\n      dysfunction hormone evaluation, laboratory blood tests, vital signs, penile ultrasound\n      (optional), echocardiogram, chest x-ray,  and endothelial function assessment (Endopat).\n\n      The adipose tissue sample is sent to Celltex's state-of-the-art laboratory in Houston,\n      Texas.  For those subjects in the placebo arm, the stem cells will be frozen for later use\n      after one year when the patients cross over into the treatment arm. The subject (patient)\n      will receive an infusion of either autologous stem cells (cells made from his own fat\n      tissue) or placebo every 2 weeks for 3 months.  Placebo will be in the form of normal\n      saline.  Subjects will be closely monitored every two weeks for first 3 months and once the\n      treatment is complete, subjects will be monitored every 3 months for the first year.   Each\n      of the previously mentioned tests will be performed at the 3, 6, 9, and 12 month mark.\n      However, the penile ultrasound (optional) and the echocardiogram will be performed only at\n      the 3 and 12 month mark."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men 40 years of age or older\n\n          -  Men with erectile dysfunction as defined by IIEF score less than 21\n\n          -  Men with endothelial dysfunction as defined as an RHI score less than 2\n\n          -  Men with normal testosterone levels (300 ng/dl)\n\n        Exclusion Criteria:\n\n          -  Men under the age of 40\n\n          -  Men with normal erectile function\n\n          -  Men with normal endothelial function\n\n          -  Men with low testosterone levels (less than 300ng/dl)"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02107118", 
            "org_study_id": "H-34570 No.11-13-40-07"
        }, 
        "intervention": [
            {
                "arm_group_label": "ARM 1: AdMSC: stem cells", 
                "description": "Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured.  Cells are returned to the study doctor for installation into the subject every 2 weeks for 3 months.", 
                "intervention_name": "AdMSC: adipose stem cells", 
                "intervention_type": "Biological", 
                "other_name": "ARM 1: AdMSC: Adipose derived mesenchymal stem cells"
            }, 
            {
                "arm_group_label": "ARM 2 Placebo", 
                "description": "Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. For those subjects in the placebo arm, the stem cells will be frozen for later use after one year when the patients cross over into the treatment arm.", 
                "intervention_name": "Placebo Comparator", 
                "intervention_type": "Other", 
                "other_name": "ARM 2 Placebo"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Stem cells", 
            "cardiovascular disease", 
            "erectile dysfunction"
        ], 
        "lastchanged_date": "April 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77030"
                }, 
                "name": "Baylor College of Medicine"
            }, 
            "investigator": [
                {
                    "last_name": "Mohit Khera, MD, MBA, MPH", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Christopher P. Smith, MD, MBA, MSS", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "H-34570: PHASE I Study: The Use of Autologous Adipose Tissue-Derived Mesenchymal Stem Cell (AdMSC) for the Improvement of Erectile and Cardiac Function in Aging Men", 
        "other_outcome": [
            {
                "description": "The analysis will allow us to assess if stem cells can improve penile duplex. The penile duplex will be given at the 3 and 12 month visits.", 
                "measure": "Improvements in penile duplex", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "The analysis will allow us to assess if stem cells can improvement results of the echocardiogram. The echocardiogram will be done at the 3 and 12 month visits.", 
                "measure": "Improvements in echocardiogram", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "overall_contact": {
            "email": "Shatabdi.Satpathi@bcm.edu", 
            "last_name": "Shatabdi Satpathi", 
            "phone": "713-798-6839"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The analysis will allow us to assess if stem cells can improve IIEF scores. The IIEF will be given at the 3, 6, 9, and 12 month visits.", 
            "measure": "Improvements in IIEF scores of greater than 2", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02107118"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Baylor College of Medicine", 
            "investigator_full_name": "Mohit Khera", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "The analysis will allow us to assess if stem cells can improve endothelial function. The RHI scores will be reviewed at the 3, 6, 9, and 12 month visits.", 
            "measure": "Improvements in RHI (reactive hyperemic index) scores of greater than 0.3", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "source": "Baylor College of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Baylor College of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}